Baxter International (BAX) is poised for growth, given the demand for its medically essential products, coupled with transformational actions. However, inflationary pressure remains a concern.Shares of this Zacks Rank #2 (Buy) company have lost 17.9% in the past six months against the industry's 5.8% growth. The S&P 500 Index has jumped 9% in the same time frame.BAX, with a market capitalization of $18.35 billion, is a global medical technology company providing items such as kidney-dialysis equipment, infu ...